Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
The generic playbook is familiar: file an ANDA, win on price, and let scale do the rest. But in today’s market—where payers demand differentiation, litigation is rele…
Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, and—eventually—patent expiry. But in Russia, the “clock” can move in ways that are easy to miss until it’s too late.
Here’s the agitation: if you…
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Drug patent strategy is having a moment—and it’s not the one most teams are planning for.
For years, “portfolio value” has been treated like a spreadsheet exercise: count patents, map expiration dates, assign a probability of grant, and move on. But th…
Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, the most valuable “weapon” isn’t a new drug launch. It’s timing. Specifically: patent expiration intelligence.
A recent DrugPatentWatch…
Patent Expiration Intelligence: The GPO Contract Weapon Hospitals Are Ignoring Read Post »
Generic launches aren’t “surprises”—they’re signals. The edge is knowing how to read them.
Most teams treat generic forecasting like a spreadsheet exercise: pull a few patent expirations, add a buffer, and hope the market agrees. But in branded pharma,…
Pharma’s “hidden talent” isn’t in the lab—it’s in the Orange Book.
Most people think the FDA Orange Book is just a regulatory filing: a list of approved drugs, patents, and exclusivities. But if you’re trying to find who is actually building defensib…
Biotech investors love a good story. But portfolio winners are usually built on something less glamorous: how you rank risk, timing, and value across a pipeline.
That’s where two metrics—Net Present Value (NPV) and the Profitability Index (PI)—move fro…
NPV and Profitability Index: How to Rank Your Biotech R&D Portfolio Read Post »
Biopharma is entering a talent cliff—one that looks less like a spreadsheet problem and more like a competitive intelligence problem.
Here’s the hook: while everyone is focused on the “patent cliff,” recruiters are quietly preparing for a different cli…
Read the Patent Cliff: How Recruiters Find Biopharma Talent Before Competitors Do Read Post »
Stop Overstocking. Patent Intelligence Is the New Risk Control for Wholesalers.
Overstocking branded drugs isn’t just a balance-sheet problem—it’s a timing problem.
For wholesalers, the risk is rarely about demand collapsing overnight. It’s about what …
Big Pharma doesn’t just “feel” a patent cliff—it signals it.
And one of the most overlooked signals isn’t in earnings calls or press releases. It’s in the hiring patterns that follow major patent expirations—especially the quiet, operational reshufflin…
Get new actionable insights and updates from BiotechBlog
